Nature Reviews Clinical Oncology

Article	Citations
Tasadenoturev active in DIPG	1213
From little subclones grow mighty oaks	1170
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	826
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	823
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	749
Ecological management of the microbiota in patients with cancer	676
Current understanding and management of CAR T cell-associated toxicities	648
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines	562
Novel ICI–TKI combination improves HCC outcomes	545
Gut microbiota in colorectal cancer development and therapy	502
Hodgkin lymphoma: great progress with room for improvement	485
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	479
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	469
A prioritization framework for large-scale cancer screening under resource constraints: three ‘not all’ principles	464
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	451
Sacituzumab govitecan plus pembrolizumab improves outcomes	446
A new standard of care for advanced-stage urothelial carcinoma	424
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown	382
Ponatinib superior to imatinib in Ph+ ALL	341
Mortality is similar with active monitoring	339
From ESMO 2022	332
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	328
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	321
Belzutifan as a new option in pheochromocytomas and paragangliomas	319
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	318

Sacituzumab tirumotecan improves OS in mTNBC	313
Understanding and overcoming multidrug resistance in cancer	311
Emerging trends in the global burden of colorectal cancer	306
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	304
Humanized mouse models for immuno-oncology research	303
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	302
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	291
Craniospinal irradiation improves leptomeningeal metastasis control	289
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	274
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	260
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	247
Vebreltinib effective in MET-amplified NSCLC	244
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	235
Improving outcomes in patients with oesophageal cancer	229
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	227
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	207
Unresectable stage III non-small-cell lung cancer: state of the art and challenges	207
Biomarkers for immunotherapy of hepatocellular carcinoma	201
Spatial landscapes of cancers: insights and opportunities	196
MicroRNAs in oncology: a translational perspective in the era of AI	192
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	188
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	184
New CAPSTONE of SCLC therapy?	181
SHINE a light: frontline ibrutinib for MCL	178
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	164
Women with clinically node negative breast cancer can safely avoid axillary surgery	160
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’	156
Domvanalimab plus zimberelimab shows promise in upper-tract cancers	154
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma	152
Prospective comparisons support the use of navigational bronchoscopy	138
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	136
DREAMseq of therapy for BRAF-mutant melanoma	129
From ESMO 2023: advances in lung cancer	128
Circulating tumour DNA — looking beyond the blood	126
Targeting chromosomal instability in patients with cancer	124
Long-term outcomes following CAR T cell therapy: what we know so far	124
Mitigating acute chemotherapy-associated adverse events in patients with cancer	124
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	118
Multiomics STEP up in correlative analysis of response to CAR T cells	118
From the ESMO Congress 2023	114
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	112
Sentinel lymph node biopsy improves surgical management of cervical cancer	111
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	110
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	108
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	107
Newly approved cancer drugs in China — innovation and clinical benefit	103
Author Correction: Innovative approaches for lung cancer screening and interception	100
Claudin 18.2 as a novel therapeutic target	99
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	99
Clinical implications of T cell exhaustion for cancer immunotherapy	94

Lung cancer in patients who have never smoked — an emerging disease	94
Enhancing immunotherapy with tumour-responsive nanomaterials	93
Targeted biopsy reduces detection of clinically insignificant cancer	90
Less-frequent surveillance is noninferior to annual mammography	88
Second-line tarlatamab improves OS in SCLC	88
T-DXd effective as second-line therapy in G/GEJ cancers	88
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	87
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics	84
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine	82
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology	80
OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC	79
Two decades of advances in clinical oncology — lessons learned and future directions	79
Barriers in access to oncology drugs — a global crisis	78
Translating biological insights into improved management of endometrial cancer	78
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	78
BrECADD raises the bar in classical Hodgkin lymphoma	77
HSCT prolongs remission of high-risk CTCLs	77
Nirogacestat effective in desmoid tumours	68
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	63
Thermal ablation is safer than resection of colorectal liver lesions	61
Cured but breathless: the growing burden of DIILD in cancer survivors	60
Promising OS with oncolytic virotherapy	59
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	59
GPRC5D-CAR T cells active in MM	58
Non-financial conflicts of interest	55
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care	55
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	53
Promise with co-administration of CAR T cells	53
Engineering platelets as cancer therapeutics	52
Multidisciplinary management of meningiomas in the era of precision oncology	52
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	51
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	50
Exploiting bacteria for cancer immunotherapy	46
The current state of the art and future trends in RAS-targeted cancer therapies	46
Efficacy of TILs confirmed	46
Repotrectinib effective in ROS1-fusion-positive NSCLC	44
KN046 shows tolerability and activity in TNBC	43
The emerging roles of γδ T cells in cancer immunotherapy	42
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	41
Problematic crossovers in cancer drug trials	39
Neoadjuvant pembrolizumab improves outcomes	38
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	37
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	37
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	30
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib	29
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	29
National value-based pricing negotiation for oncology drugs — lessons from China	28
GPRC5D as a novel immunotherapeutic target in multiple myeloma	28
CAR T cells induce durable remission of neuroblastoma	28
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	28
Treatment of NSCLC after chemoimmunotherapy — are we making headway?	27
The changing landscape of oncology clinical trials in Latin America	26
Personalizing adjuvant therapy for patients with colorectal cancer	26
Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours	25
Menin–KMT2A interaction inhibitor shows promise	24
PERSEUS triumphs — efficacy of daratumumab confirmed in transplant-eligible NDMM	24
Laparoscopic hemihepatectomy is safe and effective	24
Epcoritamab is active in large B cell lymphomas	24
Neoadjuvant chemoimmunotherapy is effective in locally advanced cervical cancer	24
Sacituzumab tirumotecan improves OS in EGFR TKI-resistant NSCLC	23
Adjuvant chemotherapy improves OS in UTUC	23
Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	22
Laparoscopic TME is non-inferior	21
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia	19
The age of foundation models	18
Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma	18
HER2-targeted therapies beyond breast cancer — an update	17
The microbiota in radiotherapy-induced cancer immunosurveillance	17
Systemic induction therapy and the expanding frontier of bladder preservation in MIBC	17
Synthetic lethal strategies for the development of cancer therapeutics	16
Will I feel better? Raising the bar for quality of life in oncology	15
Platinum-ineligible: atezolizumab preferable	15
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?	15
Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients	15
Precision oncology for KRASG12C-mutant colorectal cancer	15
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?	15
PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations	14
The next generation of immunotherapies for lung cancers	14
Cancer mRNA vaccines: clinical advances and future opportunities	14
Early promising results with the novel KRASG12C inhibitor divarasib	14

Getting the right combination to break the epigenetic code	14
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC	14
Docetaxel-based CRT improves survival in cisplatin-ineligible patients	14
Perioperative immunotherapy for renal cell carcinoma: looking beyond the data	12
Benefit from huCAR19-IL18 cells in patients with CD19+ lymphomas after CAR T cells	12
T-DXd is effective after T-DM1	12
Engaging results with glofitamab in DLBCL	12
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer	11
Thermal immuno-nanomedicine in cancer	11
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck	11
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions	10
Dabrafenib–trametinib moves to the first line in low-grade glioma	10
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges	10
A new first-line option for advanced-stage anal squamous cell carcinoma	10
The molecular blueprint of targeted radionuclide therapy	9
Time as an unmeasured ‘dose’ in oncology: introducing time budgeting as a design principle for cancer care	9
HER2-directed therapy improves urothelial cancer outcomes	9
Towards biomarker-driven therapies for urothelial carcinoma	8
From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer	8
Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer	8
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer	8
A new era for glioma therapy — targeting mutant IDH	8
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks	8
Functional precision oncology using patient-derived assays: bridging genotype and phenotype	7
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent	7
In what clinical settings are the MASAI trial results applicable?	7
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma	7
Molecular tumour boards — current and future considerations for precision oncology	7
Targeting cuproplasia and cuproptosis in cancer	6
Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer	6
Promising results with zongertinib in advanced-stage HER2-mutant NSCLC	6
Is NETTER-2 a practice-changing trial?	6
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3	6
Dostarlimab effective in dMMR LARC	6
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	6
SUNLIGHT illuminates the activity of bevacizumab	6
Perioperative therapy effective in high-risk HCC	5
Criteria for the translation of radiomics into clinically useful tests	5
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer	5
Asciminib is safe and effective in patients with newly diagnosed CML	5
Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL	5
Circulating tumour cells for early detection of clinically relevant cancer	5
Synergy of EphB2 and PD-1 blockade	5
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins	5
FDA approvals in 2024: new options for patients across cancer types and therapeutic classes	5
Transanal TME noninferior to the laparoscopic approach	5
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions	5
The biology and therapeutic implications of heterogeneity in Barrett oesophagus and oesophageal adenocarcinoma	5
Cultivating the microbiome to enhance cancer immunotherapy	5
Targeting the glioblastoma resection margin with locoregional nanotechnologies	5
Adjuvant S-1 extends OS in biliary tract cancers	5
The SONIA trial shows the power and challenges of academic research	5
Neoantigen vaccines at the crossroads: lessons from AMPLIFY-201	5
Leptomeningeal metastatic disease: new frontiers and future directions	4
Blinatumomab improves outcomes in infant ALL	4
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach	4
Towards equitable AI in oncology	4
Envisioning trans-inclusive and trans-specific cancer care	4
Tovorafenib effective against low-grade gliomas harbouring BRAF fusions	4
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer	4
AI accurately identifies targetable alterations in lung cancer histological images	4
Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer?	4
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy	4
From WCC 2022	4
Extended neoadjuvant dostarlimab provides durable benefit in resectable dMMR solid tumours	4
Combination neoadjuvant chemotherapy improves outcomes	4
Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?	4
Early promising results with addition of an ICI and an anti-angiogenic to TACE	4
Novel combination delivers prolonged OS	4
Adjuvant nivolumab shows promise in MCC	4
Rare molecular subtypes of lung cancer	3
Progress in systemic therapy for advanced-stage urothelial carcinoma	3
Optimizing CAR T cell therapy for solid tumours: a clinical perspective	3
The development of CAR T cells for patients with CNS malignancies	3
CAR T cells show superiority over standard therapies for RRMM	3
cfDNA screening for fetal aneuploidy facilitates maternal cancer detection	3
Vorasidenib: a new hope or a false promise for patients with low-grade glioma?	3
Novel assessment of epigenetic imprinting biomarkers for the diagnosis of thyroid nodules	3
Second-line axi-cel improves overall survival	3
The global epidemiology of acute myeloid leukaemia	3
NIR-II light in clinical oncology: opportunities and challenges	3
Overall survival as a primary end point in multiple myeloma trials	3
Pharmacological reactivation of p53 in the era of precision anticancer medicine	3
Bemarituzumab enters the FIGHT	3
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours	3
Emerging importance of HER3 in tumorigenesis and cancer therapy	3
Radiotherapy can be omitted for older patients with low-risk disease	3
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology	3
Therapeutic targeting of mismatch repair-deficient cancers	3
Neoadjuvant GOLP is effective in high-risk intrahepatic cholangiocarcinoma	3
Adding perioperative durvalumab to neoadjuvant chemotherapy provides benefit in MIBC	3
THOR provides new data on the efficacy of erdafitinib	3
Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?	3
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer	3
Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders	3